The Combination of CDK 4/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive breast Cancer: a Systematic Review and Meta-analysis

BACKGROUND: The identification of the novel targeted therapy i.e., cyclin-dependent kinases (CDKs) 4/6 inhibitor as combined with the endocrine regimen revealed a considerable capability to increase the managements’ effectivity of hormone-receptor-positive (HR+) and HER2- breast cancer (BC). OBJECTI...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermansyah, Dedy, Firsty, Naufal Nandita, Alhudawy, Muhammad Nuh, Nasution, Raja Alwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Medical Sciences of Bosnia and Herzegovina 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760242/
https://www.ncbi.nlm.nih.gov/pubmed/36545458
http://dx.doi.org/10.5455/medarh.2022.76.333-342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760242/
https://www.ncbi.nlm.nih.gov/pubmed/36545458
http://dx.doi.org/10.5455/medarh.2022.76.333-342

Ejemplares similares